ReviewImmunotherapy2015
Manipulating regulatory T cells: a promising strategy to treat autoimmunity.
Review in Immunotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Regulatory T cell therapy for Sjögren's disease: From pathogenesis to targeted treatment.Journal of translational autoimmunity · 2025Review
- [Targeting Regulatory T Cells to Remodel Peripheral Immune Tolerance: Research Advances and Future Directions].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025Review
- Exploring the Immunological Role of the Microbial Composition of the Appendix and the Associated Risks of Appendectomies.Journal of personalized medicine · 2025Review
- Dual neutralization of TGF-β and IL-21 regulates Th17/Treg balance by suppressing inflammatory signalling in the splenic lymphocytes of Staphylococcus aureus infection-induced septic arthritic mice.Immunologic research · 2025Article
- CPT-11 mitigates autoimmune diseases by suppressing effector T cells without affecting long-term anti-tumor immunity.Cell death discovery · 2024Article
- Therapeutic Strategies for Immune Transformation in Parkinson's Disease.Journal of Parkinson's disease · 2022Review
- Role of Cytokines in Thymic Regulatory T Cell Generation: Overview and Updates.Frontiers in immunology · 2022Review
- Cell-based therapies for rheumatoid arthritis: opportunities and challenges.Therapeutic advances in musculoskeletal disease · 2022Review
- The Liver and the Hepatic Immune Response inPathogens (Basel, Switzerland) · 2021Review
- Mannose Treatment: A Promising Novel Strategy to Suppress Inflammation.Frontiers in immunology · 2021Review
- MCL-1 is essential for survival but dispensable for metabolic fitness of FOXP3Cell death and differentiation · 2020Article
- Regulatory T Cell Plasticity and Stability and Autoimmune Diseases.Clinical reviews in allergy & immunology · 2020Review
- Adoptive Treg Cell Therapy in a Patient With Systemic Lupus Erythematosus.Arthritis & rheumatology (Hoboken, N.J.) · 2019Article
- A Novel Liposome Formulation Carrying Both an Insulin Peptide and a Ligand for Invariant Natural Killer T Cells Induces Accumulation of Regulatory T Cells to Islets in Nonobese Diabetic Mice.Journal of diabetes research · 2019Article
- Adoptive Induced Antigen-Specific Treg Cells Reverse Inflammation in Collagen-Induced Arthritis Mouse Model.Inflammation · 2018Article
- Immunoregulatory Effects of Myeloid-Derived Suppressor Cell Exosomes in Mouse Model of Autoimmune Alopecia Areata.Frontiers in immunology · 2018Article
- Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Diseases: From Mechanistic Insights to Biomarkers.Frontiers in immunology · 2018Review
- Janus-Faced Myeloid-Derived Suppressor Cell Exosomes for the Good and the Bad in Cancer and Autoimmune Disease.Frontiers in immunology · 2018Review
- Engineered Tolerance: Tailoring Development, Function, and Antigen-Specificity of Regulatory T Cells.Frontiers in immunology · 2017Review
- Changes in Immunogenicity during the Development of Urinary Bladder Cancer: A Preliminary Study.International journal of molecular sciences · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
CD4(+)CD25(+)Foxp3(+)regulatory T cells (Treg cells) are extremely important in maintaining immune tolerance. Manipulation of Treg cells, especially autoantigen-specific Treg cells is a promising approach for treatments of autoimmune disease since Treg cells may provide the advantage of antigen specificity without overall immune suppression. However, the clinical application of Treg cells has long been limited due to low numbers of Treg cells and the difficulty in identifying their antigen specificity. In this review, we summarize studies that demonstrate regression of autoimmune diseases using Treg cells as therapeutics. We also discuss approaches to generate polyclonal and autoantigen-specific Treg cells in vitro and in vivo. We also discuss our recent study that describes a novel approach of generating autoantigen-specific Treg cells in vivo and restoring immune tolerance by two steps apoptosis-antigen therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.